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criteria. The outcomes include limb revascularization,
amputation, and death. We focus in particular on the
risk factors that help to predict the mortality rate among
these patients.
METHODS
This prospective study period extended from January
1983 to January 1998. During this time more than 28,000
lower extremity vascular laboratory studies, representing
4669 patients, were performed at the Pittsburgh Veterans
Administration (VA) Medical Center. At each visit to the
laboratory, a registered nurse obtained a detailed lower
extremity vascular history of each patient. Most patients
were considered to be reliable, and clinical variables were
obtained through patient interviews. A history of smoking
was obtained by questioning the patient. Racial information
was reported by the patients. Patients were questioned
about whether the following conditions had been diag-
nosed by their physicians: hypertension, diabetes, angina,
myocardial infarction (MI), and stroke. In the case of a pos-
itive answer, a yes was recorded for angina, MI, and stroke.
For diabetes and hypertension, the patient was asked about
the type of therapy, and the answer was recorded. A yes
answer for angina, stroke, and MI was confirmed with fur-
ther questioning about specific symptoms to ensure that the
patient correctly understood the question. In this context,
angina was defined as exertional chest pain or discomfort
alleviated by rest or nitroglycerin, and stroke was defined as
a focal neurologic deficit lasting more than 24 hours. For
the small proportion of patients who were unreliable (esti-
mated at < 5% of the total), medical history information was
Intermittent claudication is a common clinical condi-
tion estimated to affect at least 10% of individuals older
than 70 years.1-3 It is widely agreed that adverse limb out-
comes such as gangrene and amputation are relatively rare
among patients with claudication. However, adverse out-
comes of systemic atherosclerosis, including death, are
common.3 Even after adjustment for known risk factors,
claudicants exhibit a higher mortality rate than the healthy
population.3 Although these generalizations are undoubt-
edly true in the aggregate, there is a paucity of data to help
the clinician predict outcomes in an individual patient.
Relatively few studies of outcome prediction have focused
specifically on claudicants.4-8 Some of these reports7,8 pre-
date the widespread use of noninvasive vascular testing,
whereas others are small or have short follow-up.4-6
In this current study, we report an analysis of long-
term outcomes among 2777 male claudicants identified
with both clinical history and noninvasive laboratory
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Objective: The purpose of this study was to delineate the natural history of claudication and determine risk factors
for death.
Methods: We reviewed the key outcomes (death, revascularization, amputation) in 2777 male patients with claudication
identified over 15 years at a Veterans Administration hospital with both clinical and noninvasive criteria. Patients with
rest pain or ulcers were excluded. Data were analyzed with life-table and Cox hazard models.
Results: The mean follow-up was 47 months. The cohort exhibited a mortality rate of 12% per year, which was signif-
icantly (P < .05) more than the age-adjusted US male population. Among the deaths in which the cause was known,
66% were due to heart disease. We examined several baseline risk factors in a multivariate Cox model. Four were sig-
nificant (P < .01) independent predictors of death: older age (relative risk [RR] = 1.3 per decade), lower ankle-brachial
index (RR = 1.2 for 0.2 change), diabetes requiring medication (RR = 1.4), and stroke (RR = 1.4). The model can be
used to estimate the mortality rate for specific patients. Surprisingly, a history of angina and myocardial infarction was
not a significant predictor. Major and minor amputations had a 10-year cumulative rate less than 10%. Revascularization
procedures occurred with a 10-year cumulative rate of 18%.
Conclusions: We found a high mortality rate in this large cohort and four independent risk factors that have a large
impact on survival. Risk stratification with our model may be useful in determining an overall therapeutic plan for clau-
dicants. A history of angina and myocardial infarction was not a useful predictor of death, suggesting that many
patients in our cohort presented with claudication before having coronary artery symptoms. Our data also indicate that
claudicants have a low risk of major amputation at 10-year follow-up. (J Vasc Surg 2001;33:251-8.)
obtained from the computerized medical record system.
Nurses had the option of leaving any field blank if a definite
affirmative or negative answer could not be obtained. Blood
pressures were obtained in both arms, and a lower extrem-
ity study was performed. For this study, we used the base-
line values of each of the analyzed variables (ie, the value
recorded at the time of the first study). Females were
excluded from the current study because few women pre-
sented for vascular laboratory testing at the Pittsburgh VA
during the study period. Male patients were identified as
claudicants if they met all of the following criteria:
1. History of chronic lower extremity pain in buttock,
thigh, or calf consistently brought on by ambulation
2. Relief of pain after 5 minutes or less of rest 
3. Absence of ischemic rest pain and ulceration
4. Noninvasive laboratory criteria for the symptomatic
extremity:
a. Resting ankle-brachial index (ABI) on the symp-
tomatic side less than 0.9, or
b. Treadmill exercise–induced reduction of ABI by
more than 0.29, or
c. Among patients with noncompressible vessels (ABI >
1.25), elimination of reflected wave and a more than
50% reduction in amplitude of pulse volume record-
ing (PVR) at ankle, in comparison with thigh PVR
Among patients meeting criteria 1, 2, and 3, we iden-
tified 2418 patients meeting criterion 4, a. An additional
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Fig 1. Kaplan-Meier survival curves for study cohort (solid line) and for age-adjusted healthy US male population (dotted line). A 95%
CI is shown for study cohort survival curve.
Table I. Clinical and demographic caharcteristics
Variable Mean (SD) %
Age (y), 64.7 (8.4)
Pack/y smoking, mean 53.7 (26.0)
ABI, mean 0.58 (0.21)
Race
White 87%
Nonwhite 13%
Diabetes
No diabetes 62.0%
Diet-controlled 6.9%
Oral hypoglycemic therapy 12.8%
Insulin therapy 18.4%
Smoking
Never smoked 6.0%
Past smoker 36.6%
Current smoker 57.4%
Hypertension
No hypertension 54.0%
Hypertension, no drug therapy 3.7%
Hypertension, drug therapy 42.3%
Angina
No 77.9%
Yes 22.1%
MI
No 70.6%
Yes 29.4%
Prior CVA
No 82.9%
Yes 17.1
194 patients met criterion 4, b, and a final group of 165
patients met criterion 4, c. This yielded the study group of
2777 patients.
To estimate the validity of the medical history infor-
mation collected by the nurses in the vascular laboratory,
one of the authors performed a blinded review of the
medical records of 241 randomly selected patients. In this
manner we obtained independent medical record informa-
tion about hypertension, diabetes, angina, MI, cere-
brovascular accident (CVA), and smoking history.
Comparison of these data with the vascular laboratory
data for these variables showed an excellent agreement for
each variable: hypertension, 88%; diabetes, 91%; angina,
92%; MI, 94%; CVA, 90%; and smoking, 93%.
Outcome events were extracted from two VA national
databases (beneficiary identification and record locator
subsystem and the national patient care database) as well
as from hospital records. The national VA databases have
been validated with studies that show accuracy rates of
more than 95% by comparison with direct patient record
review (described at www.virec.research.med.va.gov). The
follow-up databases we used for this study are designed to
track veteran mortality rates regardless of the location of
death. In addition, revascularization and amputation pro-
cedures are tracked for all VA hospitals. This allowed us to
track these outcomes wherever they may have occurred in
the VA system. However, revascularization and amputa-
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tion may be incomplete because of the possibility of veter-
ans undergoing some procedures outside the VA. Missing
data across the database were relatively infrequent, rang-
ing from 0% for the most fully populated field (patient
identification) to 8% for the field with the greatest pro-
portion of missing data (pulse pressure).
Point values for different risk factors in multivariate
modeling were developed with previously described meth-
ods.9 Expected survival for the cohort (the “normal” sur-
vival curve in Fig 1) was computed by the use of
Hakulinen’s method10 with internal rate tables in S-PLUS
(Mathsoft, Cambridge, Mass). With this method, a cohort
survival curve is computed that is an average of the indi-
vidual expected survival curves for referents from the
national population, matched for age, sex, and year of
entry. In addition, this method also recreates a similar cen-
soring pattern in the expected survival function. In our
analyses, we used Access (Microsoft, Redmond, Wash) for
descriptive statistics and SAS (SAS Institute, Cary, NC) for
Cox proportional hazards modeling, Kaplan-Meier plots,
and parametric modeling.
RESULTS
Table I shows general demographic and clinical charac-
teristics of the patient cohort. Aside from the fact that all
the patients are males, the cohort has characteristics typical
of patients with vascular disease in other studies, including
Fig 2. Kaplan-Meier curves showing probability of freedom from selected limb-related events: minor amputation, major amputation,
and surgical revascularization.
a similar age, race, smoking history, and other similar car-
diovascular risk factors. The mean patient follow-up in our
study was 47 months. A total of 1363 patients died during
follow-up. The survival curve (Kaplan-Meier method) for
the entire group is shown in Fig l (solid line), along with a
95% CI. By fitting an exponential parametric model, we
calculated the annual mortality risk among our patients as
12% of the at-risk group. The usefulness of this summary
statistic was assessed by determining that the survival data
closely fit the exponential model (residual deviance χ2 <
0.0005). The mortality rate among the claudication cohort
was significantly (P < .05) greater than the mortality rate of
the age-adjusted “normal” male population of the United
States (Fig 1, dotted line). We were able to ascertain the
cause of death for a subset consisting of 236 patients who
died in the hospital. Sixty-six percent of these patients died
of ischemic cardiac events.
Fig 2 shows the Kaplan-Meier plot of the occurrence
of three important limb-related events: minor amputation
(below ankle level), major amputation (above ankle level),
and surgical revascularization. Minor and major amputa-
tions occurred with a 10-year cumulative frequency of less
than 10%. The 10-year cumulative frequency of surgical
revascularization was 18%.
We next sought to delineate the factors that predict
the time to death among our patient cohort. Table II
shows the results of univariate Cox proportional hazards
modeling of a number of potential predictors. The five
factors that had significant predictive value were age, ABI,
diabetes, history of CVA, and pulse pressure. We noted
that diet-controlled diabetes was not a significant risk fac-
tor, but that diabetes that required oral agents for treat-
ment and diabetes requiring insulin were both significant
predictors with roughly equal predictive weight.
Therefore, for subsequent analysis, we used the variable
“diabetes requiring medication.” Using the multivariate
Cox modeling of the five factors identified with univariate
analysis, we found that four were independent predictors
of death: age, history of CVA, ABI, and diabetes requiring
medication (pulse pressure was the one variable that did
not retain predictive value in the multivariate model). The
upper section of Table III shows the model parameters for
this initial multivariate model.
A second multivariate model (Table III, lower section)
was developed after dividing age and ABI into appropriate
categories. This second model lends itself to a point sys-
tem, wherein any given patient can be assigned a “risk
score” by adding the appropriate point values shown in
Table III. Fig 3 shows the predicted 2-year mortality rate
(and 95% CI) for claudicants as a function of the risk
score, on the basis of our multivariate Cox model. For
comparison, we have shown the actual 2-year mortality
data for our patient cohort as a function of risk score
(closed circles in Fig 3).
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Table II. Univariate prediction of time to death in claudicants
Variable β Value RR P value
Age (y) .0321 1.03 < .0005
Smoking
Never smoked (Baseline)
Past smoker .1435 1.15 NS
Current smoker .0473 1.04 NS
Smoking (pack/y) .0016 1.00 NS
Race
White (Baseline)
Nonwhite –.0352 0.97 NS
ABI –1.0522 0.35 NS
Pulse pressure .0047 1.00 .0017
Systolic pressure .0005 1.00 NS
Hypertension
No hypertension (Baseline)
Hypertension, no drug therapy –.0529 0.95 NS
Hypertension, no drug therapy .0403 1.04 NS
Diabetes
No diabetes (Baseline)
Diet-controlled .0122 1.01 NS
Oral hypoglycemic therapy .3631 1.44 < .0005
Insulin therapy .4236 1.53 < .0005
Angina (yes, no) .0935 1.10 NS
Prior MI (yes, no) .0820 1.09 NS
Symptomatic CAD (yes, no) .0711 1.07 NS
Prior CVA (yes, no) .4229 1.53 < .0005
β Values and RR were calculated with the univariate proportional hazards model. The β value is the natural logarithm of RR. In the case of continuous vari-
ables (age, smoking pack/years, ABI, pulse pressure, systolic pressure), the RR specifies the risk multiplier for a one-unit change in the variable. As a result,
the RR may seem low even when the variable in question is a strong predictor. In the case of the other variables, the RR indicates the increased RR associ-
ated with having the risk factor. “Symptomatic CAD” is defined as the presence of either angina or prior MI.
ABI, Ankle-brachial index; CAD, coronary artery disease; CVA, cerebrovascular accident; MI, myocardial infarction; NS, not statistically significant; RR,
relative risk.
DISCUSSION
This study represents one of the largest in which the out-
comes among claudicants are examined. We have docu-
mented various outcomes (mortality rate, major and minor
amputation, revascularization) among a large cohort of clau-
dicants, using methods that allow for long-term national 
follow-up. In comparison with older large studies of claudi-
cants,7,8 one strength of the current analysis is that claudi-
cants were identified with both clinical and noninvasive
criteria; thus, we avoided including patients with nonvascu-
lar leg pain. Our choice of the resting and treadmill ABI cri-
teria (“Methods” section) for diagnosing peripheral vascular
disease is consistent with several other studies.3,11-13
Although practitioners routinely rely on PVR tracings when
patients have noncompressible vasculature,3 there are no
widely accepted criteria for what constitutes a significant
reduction in PVR waveform. We used the same criterion that
we use in our clinical practice (> 50% reduction of amplitude
from thigh to ankle and loss of reflected wave at the ankle
level). In any event, less than 6% of the study group was
entered on the basis of PVR criteria.
The mortality rates observed in our study population
are striking, with an annualized mortality risk of 12%.
Five- and 10-year mortality rates were 42% and 65%,
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respectively. In comparison, Dormandy et al14 recently
analyzed a large number of previous studies and found
that 5- and 10-year mortality rates among claudicants
averaged 30% and 50%, respectively. These differences may
be related to the fact that most previous studies have
included both men and women (women are lacking in our
study and are known to have a longer life expectancy).
Our data further show that adverse limb ischemic
events such as minor and major amputation are relatively
infrequent among claudicants (Fig 2). These findings are
consistent with those of many previous studies.3
We have also developed a predictive model to help
stratify claudicants according to the risk of death. It is
widely accepted that claudication is a marker for systemic
atherosclerosis, leading to future cardiovascular death and
morbidity. However, there are no well-established criteria
allowing the clinician to predict outcomes in individual
patients. Understanding the natural history, especially the
likelihood of death, is crucial to clinical decisions, such as
whether to offer surgical revascularization.
The four variables that have independent predictive
value for the time to death were age, prior CVA, ABI, and
diabetes requiring medication. In principle, Model 1 in
Table III could be used to calculate the mortality risk for
Table III. Multivariate prediction of risk of death in claudication patients
Model 1
Variable β value RR P value
Age (y) .0308 1.03 < .0005
Prior CVA (yes, no) .3193 1.38 < .0005
ABI –.8673 0.42 < .0005
Pulse pressure –.0022 1.00 NS
Diabetes requiring medication (yes, no) .3641 1.44 < .0005
Model 2
Variable β value RR P value Point value*
Age
< 50 y Baseline characteristic (RR = 1) 0
50-59 y .4771 1.61 .0128 2
60-69 y .7035 2.02 .0001 3
70-79 y .9221 2.51 < .0005 4
80+ y 1.4229 4.15 < .0005 7
Diabetes requiring medication
No Baseline characteristic (RR = 1) 0
Yes .3527 1.42 < .0005 2
Prior CVA
No Baseline characteristic (RR = 1) 0
Yes .3183 1.37 < .0005 2
ABI
< 0.3 .8260 2.28 < .0005 4
≥ 0.3 and < 0.5 .3430 1.41 < .0005 2
≥ 0.5 and < 0.7 .2158 1.24 .0038 1
≥ 0.7 Baseline characteristic (RR = 1) 0
Total possible points 15
β Values and RR were calculated with the multivariate proportional hazards model. Further description of the β and RR values can be found in Table II.
*Point values are based on assigning a value of 1 to the smallest β value (.2158). Therefore, multiplication factor applied to the β’s was 1/.2158 = 4.6.
Point values are rounded to the nearest integer. 
ABI, Ankle-brachial index; CVA, cerebrovascular accident; NS, not statistically significant; RR, relative risk.
individual claudicants. However, Model 2 lends itself to a
convenient point system. For any given claudicants, the
appropriate point values are summed and yield a risk score.
Fig 3 shows the predicted 2-year mortality rate as a func-
tion of risk score. The choice of a 2-year mortality rate was
somewhat arbitrary, because we could have chosen any
mortality end point for this figure. We think that a 2-year
mortality prediction may be useful in patient education
and in the determination of the focus of patient care.
Because limb amputation is infrequent among claudicants,
the primary purpose of revascularization is to improve the
quality of life. Therefore, patients with a high predicted
mortality rate may be better served with aggressive cardiac
risk factor intervention than with aggressive intervention
for claudication. In any specific case, the clinician and
patient will still need to factor in the severity of the clau-
dication and the degree of lifestyle impairment.
Our finding of the importance of an ABI as a predictor
of death is consistent with previous work5,11,15 and appears
to confirm again the correlation between the severity of
peripheral and coronary arterial disease. The important
role of diabetes has also been previously demon-
strated.5,6,16 We found that diet-controlled diabetes was
not a significant predictor; however, diabetes that required
either oral or insulin therapy was a strong predictor of
reduced life expectancy. This finding is consistent with
recent work showing that glucose control, not the mere
presence of diabetes, is the critical factor in determining the
likelihood of complications from diabetes. In our study
group, a history of CVA was an important predictor of time
to death. To our knowledge, the relevance of this variable
has not been previously emphasized.
Our analysis is also notable for the variables that were
found not to be significant predictors of time to death.
Although smoking, angina, a history of MI, and a history
of hypertension all correlated with reduced life expectancy,
the correlations were not statistically significant (Table II).
In the case of smoking, the issue may simply be that large
numbers of patients in our study group (94%) were cur-
rent or past smokers. The small number of nonsmokers
may have made it difficult to determine the true predictive
value of smoking. The lack of predictive value for a base-
line history of angina and MI is at odds with the findings
of other studies.5,7,17 It may be that many of our patients
presented with claudication before presenting with coro-
nary symptoms. Other means of cardiac assessment (eg,
electrocardiography, nuclear imaging, cardiac catheteriza-
tion) may have proved to be better predictors of death. It
is also possible that patients who have a diagnosis of coro-
nary disease are more closely followed up and treated for
the disease. In any case, our data demonstrate the poten-
tial pitfall of relying on cardiac history alone as a means of
predicting the mortality rate. Hypertension has been pre-
viously identified as a predictor of death among claudi-
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Fig 3. Predicted 2-year mortality rate of male claudicants as a function of risk score (computed with point system shown in Table III).
A 95% CI is shown for mortality estimate. Figure also shows raw 2-year mortality rate for our study cohort, as a function of risk score
(closed circles). Number of patients with risk scores of 12 and 13 is small, so raw 2-year mortality data points for these scores should be
interpreted with caution.
cants.5-7 Although we did not find that a history of hyper-
tension was a significant predictor, an elevated pulse pres-
sure was a predictor in univariate analysis (Table II). In
previous work in which the progression of carotid disease
was studied,18,19 we documented the importance of pulse
pressure. In the current analysis, pulse pressure did not
retain significance in the multivariate models.
An important limitation of our study population is the
lack of women. This is virtually inevitable, given the set-
ting of this study (VA Hospital). Additionally, our study
included few Hispanic patients, because of the makeup of
the veteran population in the western Pennsylvania region.
In other respects, however, the demographic and clinical
characteristics of our study population (Table I) are not
much different from that seen in other vascular laborato-
ries. Female claudicants are likely to have a natural history
different from males. In the interpretation of our natural
history data, it should also be noted that not all claudi-
cants are referred for noninvasive evaluation. Therefore,
our results should only be extrapolated to other male clau-
dicants with claudication of sufficient severity to be
referred to a noninvasive vascular laboratory.
Although our model provides a close fit to our patient
cohort (Fig 3), the true test is the applicability of the
model to other male claudicants. We are currently gather-
ing data on new patients both within and without the VA
system to conduct such analysis in the future.
CONCLUSIONS
Among a large, prospectively followed cohort of male
claudicants with long-term national follow-up, we have
defined risk factors that predict death. By the use of a point
system, four easily identifiable factors (age, diabetes, history
of CVA, and ABI) can be used to stratify patients into groups
with differing predicted mortality rates. These data may be
helpful in clinical decision making in the care of claudicants.
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DISCUSSION
Dr Walter J. McCarthy III (Chicago, Ill). Dr Porter, Dr
Riles, Dr Pearce, members, and guests. It’s an honor to discuss
this interesting paper.
The authors have brought to our attention the problem of
intermittent claudication, which is a remarkably prevalent condi-
tion affecting as many as 10% of North Americans older than 70
years. By some estimates, there are at least 4 million to 5 million
Americans with intermittent claudication, and the proper man-
agement of this huge patient cohort remains controversial. For
this reason, natural history information, such as that contained in
the present study, is invaluable. The authors have captured a huge
group of patients within their own VA Hospital and then used
two VA national databases for the follow-up end points. This is an
ingenious technique because it avoids the almost impossible task
of following up on all these patients using the usual methods.
My first question relates to the accuracy of these two VA
databases. Are you sure that the data are really sound? Did you do
some sampling of, say, 100 of your patients and then go back and
use record reviews and telephone interviews to compare your own
results with the databases? Did you use the national death index
registry to confirm the mortality rate?
My remaining questions relate to the analysis and the pre-
sentation of the data because you certainly have a great deal of
very valuable data. Which of these patients had iliac as compared
with superficial femoral disease, and how did that affect their
prognosis? That’s a question that all of us wonder about.
Was revascularization used for limb salvage as the disease pro-
gressed over the years or was it used simply to relieve the claudi-
cation symptoms?
Did you calculate a correlation coefficient for the relationship
between the ankle-brachial index and the length of life? This is a
number that would be very interesting, and this relationship is
something unique in your research, I think.
Finally, you couldn’t show that smoking was a predictor of
early death in your univariate analysis because 94% of your
patients smoked; however, you could perform a subgroup analy-
sis comparing the current smokers with the past smokers and then
try and show a difference in length of life and also trying to pre-
dict the amputation rate. That would help us with our argument
to patients that they should stop smoking.
I congratulate the authors on their manuscript and on their
effort and look forward to seeing the final published paper.
Thank you.
Dr Satish C. Muluk. Thank you, Dr McCarthy, for your com-
ments.
An important issue that you raise is the accuracy of the data-
bases that we used. Obviously that’s central to the validity of the
study. The databases have been validated by independent study, and
they reportedly have an accuracy rate of greater than 95%. We did
not perform any validation on our own, although we did to the
extent that we could confirm deaths within the hospital. Obviously,
that represents only a small subset, and we didn’t think that it was
valid to use that information as a way of validating the database itself.
On the other hand, the data that we had available to us showed
excellent validity of the VA database. But I think the key point is that
there has been independent validation of these VA databases.
I would point out that one of them, the BIRLS, is actually
used for benefit payments to surviving relatives, and so there is a
great deal of effort that goes into making it accurate. Obviously
it has to do with payments given to people who survive, and
therefore, it’s quite important for the government to maintain
accuracy of that.
The question you asked about iliac versus SFA disease is very
important to us as well. We did not study that for this paper, but
that’s in fact the next step that we propose to do.
One of the other questions you asked was whether the surg-
eries were done for claudication or limb salvage. Although we did
not report it in the manuscript specifically, I can tell you that the
vast majority of operations was done for claudication. Only a few
of the operations, representing the small number done after the
first year or two after enrollment, were done for limb salvage, rep-
resenting the fact that very few of these patients actually went on
to have limb-threatening ischemia.
We did correlate ankle-brachial index with the length of life.
The specific correlation there is not evident in the fairly sophisti-
cated statistical analysis we did because we felt it was more useful
to view it as a part of a multivariate model, but there is no ques-
tion that independently, as a single factor, ankle-brachial index
does predict length of life in a statistically striking manner. And
the risk ratio associated with that univariate analysis is about 1.4
for every 0.2 points of change in the ankle-brachial index.
Finally, the issue of smoking you raised, whether we com-
pared current versus past smoking as a factor. We did indeed do
this analysis, but found that it was not an important factor. I hon-
estly think that a lot of it has to do with patients simply not being
truthful about their smoking habits. And probably the percentage
of current smokers is truly higher than we indicate because
patients know what to tell their doctors to make them happy, and
I think that’s what’s going on in this instance. 
Dr Donald L. Jacobs (St Louis, Mo). Your patient population
is a vascular lab patient population. Since that’s a different popu-
lation than the one that would actually get vascular surgery con-
sultation, do you know the percentage of these patients that were
referred to the vascular clinic?
Dr Muluk. That’s a good question. I’m afraid I don’t have
that answer. I would suspect, because of the structure of our VA,
that a large number of them would have been seen in the vascu-
lar clinic because we typically see all of the claudicants at least
once; it’s just the nature of our setup at the Pittsburgh VA. So I
would think the percentage is quite high, but I don’t know the
exact number.
Dr Porter. But you do know that vascular lab–selected patients
have already gone through a preselection process?
Dr Muluk. They have gone through a preselection done by
some physician, that’s absolutely correct.
Dr Enrique Criado-Pallares (Madrid, Spain). Obviously, the
ABI has a strong prognostic value for revascularization and limb
salvage. You didn’t tell us what the amputation and revasculariza-
tion rate was for the patients with ABIs below 0.3.
Dr Muluk. Although there was a trend toward lower ankle-
brachial index and major amputation, the trend was not statisti-
cally significant. And I think perhaps it’s telling us that patients
with low ankle-brachial index who only have claudication as a
symptom are still not at that high a risk for limb loss, at least that’s
what our data would suggest.
Dr Keith D. Calligaro (Philadelphia, Pa). Did I understand
you right that only approximately 400 patients underwent exer-
cise studies?
Dr Muluk. No. A large number of patients underwent exercise
studies, but what I showed there was that if a patient had an
ankle-brachial index less than 0.9, they were enrolled as a claudi-
cant on that basis alone. The other numbers represented the
patients who had a resting ankle-brachial index greater than 0.9
but were still enrolled as claudicants because of an appropriate
reduction with exercise.
Dr Calligaro. How many underwent exercise studies?
Dr Muluk. To be honest, I can’t give you that number off the
top of my head, but my guess is that roughly half of the patients
who present for claudication undergo exercise treadmill testing.
Dr Calligaro. I would submit that potentially instead of this
being a report of 2800 claudicants that it may be a report of 1400
claudicants. Although the majority of patients with a resting
ankle-brachial index less than 0.9 and with classic symptoms will
probably have claudication, I don’t think you can assume they all
have claudication on an arterial basis; they may have it because of
some other cause. Your data may be somewhat flawed because
you may be including some patients with lumbosacral spine dis-
ease who are having calf aching.
Dr Muluk. Well, I’d being willing to compromise and go
down to 2400, but I really think that the majority of patients who
have resting ABIs less than 0.9 and appropriate symptoms proba-
bly have claudication. But I do agree with you that I think in a
more modern study that exercise treadmill testing would be done
for everyone. This study was initiated many years ago, and of
course, it wasn’t as prevalent.
Dr Porter. Dr Calligaro, would you have insisted on a 20%
pressure drop for study entry in all patients who presented?
Dr Calligaro. If they could complete the study.
Dr Porter. Okay. Well, I just wanted to get your position there.
Dr Robert B. Patterson (Providence, RI). At what point in
their claudication history were these patients? I was interested
that your curves were very flat after 2 years for amputation and
revascularization, and I wonder if you can correlate that with the
duration of symptoms? Were you catching some patients on a
progressive downward trend and the rest of them represented a
stable population?
Dr Muluk. That’s an excellent question. Unfortunately, the
only point that we have for certainty is the point of their first vas-
cular lab study and that was the point of origin for this study. We
did not actually record, which is an oversight, the length of symp-
toms prior to presentation at the lab. Therefore, I can’t answer
that question although it’s a very good one.
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